Aktie A0YB73 D. WESTERN THERAPEUTICS INSTITUTE, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen D. Western Therapeutics Institute, Inc.

Aktien

A0YB73

JP3548740004

4576

Markt geschlossen - Japan Exchange
Andere Börsenplätze
 08:00:00 02.05.2024 		% 5 Tage % 1. Jan.
110 JPY +4.76% Intraday Chart für D. Western Therapeutics Institute, Inc. +7.84% -21.99%
14.02. D. Western Therapeutics Institute, Inc. gibt eine konsolidierte und nicht konsolidierte Gewinnprognose für das am 31. Dezember 2024 endende Geschäftsjahr ab CI
2023 D. Western Therapeutics Institute, Inc. gibt eine konsolidierte Gewinnprognose für das am 31. Dezember 2023 endende Jahr ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2023
D Western Therapeutics Institute : Summary of Consolidated Financial Results for the Six Months Ended June 30, 2023(Based on Japanese GAAP)
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024
D. Western Therapeutics Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023
D Western Therapeutics Institute : FY12/22 Financial Results Briefing Materials
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022
D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.
D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥901.216203 million in funding from Whiz Partners Inc.
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022
D Western Therapeutics Institute : Summary of Consolidated Financial Results for the Year Ended December 31, 2021(Based on Japanese GAAP)
D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
D. Western Therapeutics Institute, Inc. Announces Consolidated Earnings Results for the Six Months Ended June 30, 2021
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
UBiENCE Inc. announced that it expects to receive ¥100 million in funding from D. Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2021
D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2021
D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2020
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0YB73 Aktie
  4. Nachrichten D. Western Therapeutics Institute, Inc.
  5. Andere Sprachen